{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-006506","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.118273+00:00","generated_at":"2026-06-27T00:13:41.246961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell reports Q4 net loss $0.17/sh; cash $55.7M; Roche deal up to $670M","bullets":["Q4 2021 net loss $29.0M ($0.17/sh) vs net income $2.0M ($0.01/sh) in Q4 2020; FY 2021 net loss $43.0M ($0.26/sh).","Cash and equivalents $55.7M at Dec 31, 2021; received $50M upfront from Roche/Genentech OpRegen collaboration in Jan 2022.","Roche/Genentech deal for OpRegen (RG6501) worth up to $670M plus double-digit royalties; four dry AMD patients showed retinal restoration.","R&D expenses $24.8M in Q4, driven by $21.0M accrual for future obligations to Israel Innovation Authority and Hadasit.","2022 milestones include new pipeline program announcement, OPC1 manufacturing improvements, and VAC2 IND submission in 2H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-006506","json":"https://secwatch.observer/filing/0001493152-22-006506.json","markdown":"https://secwatch.observer/filing/0001493152-22-006506.md","text":"https://secwatch.observer/filing/0001493152-22-006506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222006506/0001493152-22-006506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222006506/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:13:41.246961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}